

GHG UPDATE

General



- RTTQA group funding
 - Funding approved for 3 year period 2016-19
 - Guaranteed for 2016-17

Thank you to those groups that provided letters of support for submission with the review document

- RTTQA group IT infrastructure
 - Highlighted as requiring further investment to provide a more efficient QA service
- Naming convention
 - Continue to implement for all new trials
- Protocol variation definitions
 - Continue to implement for all new trials

Workload



Trial QA portfolio

QA Current trials – 24

Funded trials QA in development – 19

Complexity of trials has increased

Increase in rarer cancer trials

Need for international collaboration

Collaborative trials work


HYBRID & RAIDER – TROG

InPaCT – IROC

ROAM – EORTC (TROG)

PATHOS/BEST-OF – EORTC

RADICALS – TROG



Acceptance of UK QA

By both TROG and EORTC

IROC – further discussions

Dosimetry audit




National Rotational
Radiotherapy Audit

50 centres

Arc-Check also
being used and
data being
combined

Tolerances being
reviewed




National SABR Lung
dosimetry Audit

28 centres

Completed for UK
Commissioning
through evaluation
(CtE) programme

Ongoing for trials
plus paid for basis

Spinal audit planned



National Brachytherapy
HDR/PDR Audit

45 centres

1 UK centre
remaining

Publication pending



National SRS
Audit

25 centres

4 centres
remaining

National
commissioning
programme

Alanine W1 and
film

Future work



- The RTTQA group is currently running QA programmes for the following advanced techniques:
 - SABR
 - SRS/SRT
 - Adaptive radiotherapy
 - Brachytherapy
- Working groups are being established to take QA forward in areas including:
 - Protons,
 - MR-Linac
 - Molecular radiotherapy